TIGIT-CD155 interactions in melanoma

• Verfasst von: Mahnke, Karsten [VerfasserIn]
• Verfasst von: Enk, Alexander [VerfasserIn]
• Titel: TIGIT-CD155 interactions in melanoma
• Titelzusatz: a novel co-inhibitory pathway with potential for clinical intervention
• Verf.angabe: Karsten Mahnke and Alexander H. Enk
• E-Jahr: 2016
• Jahr: 4 January 2016
• Umfang: 3 S.
• Fussnoten: Gesehen am 22.05.2020
• Titel Quelle: Enthalten in: The journal of investigative dermatology
• Ort Quelle: Amsterdam : Elsevier, 1938
• Jahr Quelle: 2016
• Band/Heft Quelle: 136(2016), 1, Seite 9-11
• ISSN Quelle: 1523-1747
• DOI: doi:10.1016/j.jid.2015.10.048
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Biomarkers, Tumor
• Sach-SW: Humans
• Sach-SW: Receptors, Immunologic
• Sach-SW: Receptors, Virus
• Sach-SW: RNA, Small Interfering
• K10plus-PPN: 1698699034

Abstract

Inozume et al. describe a novel immunosuppressive mechanism in melanoma that is triggered by the interaction between CD155 (expressed by melanomas) and T-cell Ig and ITIM domain (TIGIT) (expressed by tumor infiltrating lymphocytes). This pathway exists in addition to the "classical" co-inhibitory PD-1-PD-L1 pathway. Hence, the combinatorial blockage of both pathways by specific antibodies resulted in the greatly enhanced effector function of melanoma-specific cytotoxic T cells. Given that CD155-TIGIT signaling exerts potent inhibitory action in different subsets of immune cells and that CD155 is expressed broadly in several tumor entities, this report points toward a novel and promising therapeutic strategy to combine different checkpoint blocking agents for greater success in antitumor therapy.